Keep in mind the rule of 3 with IBS-C
You may have IBS-C if you are experiencing:
To diagnose IBS-C, your doctor may rule out other conditions through blood and/or stool tests, a colonoscopy, a barium enema, and psychological tests.
NOTE: IBS-C vs CIC
IBS-C can often be confused with chronic idiopathic constipation (CIC) because they share many symptoms, but the key difference in IBS-C is the frequent pain that it causes.
Along with infrequent and incomplete bowel movements, straining, and irregular stool consistency, patients with IBS-C may also experience abdominal pain, discomfort, and bloating.
To diagnose IBS-C, your doctor may rule out other conditions through blood and/or stool tests, a colonoscopy, a barium enema, and psychological tests.
NOTE: IBS-C vs CIC
IBS-C can often be confused with chronic idiopathic constipation (CIC) because they share many symptoms, but the key difference in IBS-C is the frequent pain that it causes.
Along with infrequent and incomplete bowel movements, straining, and irregular stool consistency, patients with IBS-C may also experience abdominal pain, discomfort, and bloating.
ZELNORM is the only IBS-C medicine designed to activate the bowel-moving muscles in your gut to relieve abdominal pain, bloating, and constipation. ZELNORM (tegaserod) is in a class of medications called serotonin agonists. It works by improving muscle movement and increasing production of fluid in the bowels.
ZELNORM is approved to treat IBS-C in women less than 65 years of age who have low cardiovascular risk. Talk to your doctor to see if ZELNORM is right for you.
In 2002, ZELNORM was the first prescription medication for IBS-C in the United States. ZELNORM was voluntarily withdrawn from the market in 2007 due to possible cardiovascular side effects. In early 2019, it was made available again. An FDA-appointed safety panel reviewed and unanimously approved ZELNORM for re-introduction for use in women less than 65 years of age.
Like all medications, possible side effects may occur. It’s important to tell your doctor if you have any prior risk factors. ZELNORM is for use in adult women under 65 years of age who do not have a history of ischemic cardiovascular disease and who have no more than one risk factor for cardiovascular disease. Cardiovascular disease risk factors include:
Talk to your healthcare provider about risk factors you may have for a major cardiovascular event before you start taking ZELNORM.
Before taking ZELNORM, tell your healthcare provider about all of your medical conditions, including if you:
ZELNORM™ (tegaserod) is a prescription medicine used to treat adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C).
ZELNORM is for use in adult women under 65 years of age who do not have a history of ischemic cardiovascular disease and who have no more than one risk factor for cardiovascular disease. Cardiovascular disease risk factors include active smoking, high blood pressure or history of being treated with medicines that lower blood pressure, high cholesterol or are taking medicine to lower your blood cholesterol levels, history of diabetes, age 55 years or over, or obesity. Talk to your healthcare provider about risk factors you may have for a major cardiovascular event before you start taking ZELNORM.
The most common side effects of ZELNORM are headache, stomach-area (abdominal) pain, nausea, diarrhea, gas, indigestion, and dizziness.
Before you take ZELNORM, tell your healthcare provider:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
To report possible adverse reactions, contact Alfasigma USA at 1-855-697-9232. You may also report possible adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please also see the Medication Guide within the full Prescribing Information.